Showing results (901-910 of 1,698) with videos related to

Sort By:
Pageof 170
Peptides|September 1, 2016
Expanding the pharmacological profile of κ-hefutoxin 1 and analogues: A focus on the inhibitory effect on the oncogenic channel Kv10.1Lien Moreels, Steve Peigneur, Yoko Yamaguchi, et al.
Proteins|July 15, 2018
Refined structure of BeM9 reveals arginine hand, an overlooked structural motif in scorpion toxins affecting sodium channelsNikita A Kuldyushev, Konstantin S Mineev, Antonina A Berkut, et al.
International Journal of Systematic Bacteriology|April 1, 1990
Inter- and intrafamilial similarities of rRNA cistrons of the PasteurellaceaeJ De Ley, W Mannheim, R Mutters, et al.
Alimentary Pharmacology & Therapeutics|December 1, 1993
Short report: smoking habits and the acquisition of metronidazole resistance in patients with Helicobacter pylori-related gastritisE M Witteman, W P Hopman, M C Becx, et al.
Gastroenterology|March 25, 2014
Incidence of colonic neoplasia in patients with serrated polyposis syndrome who undergo annual endoscopic surveillanceYark Hazewinkel, Kristien M A J Tytgat, Susanne van Eeden, et al.
Biochimica Et Biophysica Acta. Proteins and Proteomics|February 10, 2017
C-Terminal residues in small potassium channel blockers OdK1 and OSK3 from scorpion venom fine-tune the selectivityAlexey I Kuzmenkov, Steve Peigneur, Anton O Chugunov, et al.
Journal of Pediatric Surgery|July 16, 2019
The Effect of Gastrostomy Placement on Health-Related Quality of Life in ChildrenJosephine Franken, Rebecca K Stellato, Stefaan H A J Tytgat, et al.
Marine Drugs|August 2, 2012
Atypical reactive center Kunitz-type inhibitor from the sea anemone Heteractis crispaIrina Gladkikh, Margarita Monastyrnaya, Elena Leychenko, et al.
Marine Drugs|September 25, 2019
Magnificamide, a β-Defensin-Like Peptide from the Mucus of the Sea Anemone Heteractis magnifica, Is a Strong Inhibitor of Mammalian α-AmylasesOksana Sintsova, Irina Gladkikh, Aleksandr Kalinovskii, et al.
EJNMMI Research|August 23, 2021
Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytesThomas Blom, Rutger Meinsma, Franca di Summa, et al.
Pageof 170